Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	Related Studies

Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice

This study has been completed.
Information provided by Department of Veterans Affairs

Please refer to this study by its ClinicalTrials.gov identifier: NCT00007527

Locations


United States, New York
	Paul Casadonte, M.D. VAMC New York
	New York, New York, United States, 10010

United States, Washington
	Andrew Saxon, M.D.-Addictions Treatment (116ATC)
	Seattle, Washington, United States, 98108

Sponsors and Collaborators

Department of Veterans Affairs

National Institute on Drug Abuse (NIDA)

Reckitt and Colman